Literature DB >> 32062697

Serum immunoglobulin G4 in Sjögren's syndrome: a pilot study.

Maria Maślińska1, Bożena Wojciechowska2, Małgorzata Mańczak3, Brygida Kwiatkowska4.   

Abstract

Immunoglobulin IgG4 plays a role in the pathogenesis of the Mikulicz disease previously considered a form of primary Sjögren's syndrome (pSS). We investigated serum levels of IgG4, total IgG, C3, and C4 serum complementary components in patients suspected of Sjögren's syndrome. Basic laboratory and immunological tests, including IgG4 and IgG concentration, were performed on 20 healthy and 68 suspected of pSS individuals. We distinguished: group I: 48 pSS patients; group II (sicca): 20 patients with dryness without pSS. We revealed: statistical differences between groups I and II concerning hypergammaglobulinemia, ESR, RF, ANA, Ro, and La antibodies; lower IgG4 levels and IgG4/IgG ratio in group I compared to healthy individuals (p < 0.0435; 0.0035, respectively); no significant differences in the concentrations of IgG4 and IgG4/IgG ratio between sicca and control groups. significantly lower (p < 0.0002) C4 levels in group I compared to other groups; significant differences in C4 concentration and IgG4/IgG ratio between three groups (p = 0.0002 and p = 0.0090, respectively); a weak negative correlation between C4 and IgG (r =- 0.274) in the whole database; weak positive correlation between C4 and IgG4/IgG ratio (r = 0.237); a negative correlation of IgG4, IgG4/Ig ratio and C4 with focus score (r = - 0.281; r = - 0.327; r = - 0.406, respectively). IgG4 serum levels were significantly decreased compared to healthy subjects. IgG4 and C4 levels correlated with infiltrations in minor salivary glands. Hypergammaglobulinemia and decreased serum C4 component levels are typical for pSS.

Entities:  

Keywords:  IgG4/IgG ratio; Immunoglobulin G4; Sjögren's syndrome

Mesh:

Substances:

Year:  2020        PMID: 32062697     DOI: 10.1007/s00296-020-04529-0

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  20 in total

1.  American College of Rheumatology classification criteria for Sjögren's syndrome: a data-driven, expert consensus approach in the Sjögren's International Collaborative Clinical Alliance cohort.

Authors:  S C Shiboski; C H Shiboski; L A Criswell; A N Baer; S Challacombe; H Lanfranchi; M Schiødt; H Umehara; F Vivino; Y Zhao; Y Dong; D Greenspan; A M Heidenreich; P Helin; B Kirkham; K Kitagawa; G Larkin; M Li; T Lietman; J Lindegaard; N McNamara; K Sack; P Shirlaw; S Sugai; C Vollenweider; J Whitcher; A Wu; S Zhang; W Zhang; J S Greenspan; T E Daniels
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

Review 2.  Production of complement components by cells of the immune system.

Authors:  R Lubbers; M F van Essen; C van Kooten; L A Trouw
Journal:  Clin Exp Immunol       Date:  2017-03-24       Impact factor: 4.330

3.  Chronic bacterial infection activates autoreactive B cells and induces isotype switching and autoantigen-driven mutations.

Authors:  Sophie Jung; Jean-Nicolas Schickel; Aurélie Kern; Anne-Marie Knapp; Pierre Eftekhari; Sylvia Da Silva; Benoît Jaulhac; Robert Brink; Pauline Soulas-Sprauel; Jean-Louis Pasquali; Thierry Martin; Anne-Sophie Korganow
Journal:  Eur J Immunol       Date:  2015-11-16       Impact factor: 5.532

4.  Serologic features of primary Sjögren's syndrome: clinical and prognostic correlation.

Authors:  Mario García-Carrasco; Claudia Mendoza-Pinto; César Jiménez-Hernández; Mario Jiménez-Hernández; Arnulfo Nava-Zavala; Carlos Riebeling
Journal:  Int J Clin Rheumtol       Date:  2012-12

5.  Elevated IgG4 serum levels among primary Sjögren's syndrome patients: do they unmask underlying IgG4-related disease?

Authors:  Clio P Mavragani; George E Fragoulis; Dimitra Rontogianni; Maria Kanariou; Haralampos M Moutsopoulos
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-05       Impact factor: 4.794

6.  2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts.

Authors:  Caroline H Shiboski; Stephen C Shiboski; Raphaèle Seror; Lindsey A Criswell; Marc Labetoulle; Thomas M Lietman; Astrid Rasmussen; Hal Scofield; Claudio Vitali; Simon J Bowman; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2016-10-26       Impact factor: 19.103

7.  Spectrum of Disorders Associated with Elevated Serum IgG4 Levels Encountered in Clinical Practice.

Authors:  Jay H Ryu; Ryohei Horie; Hiroshi Sekiguchi; Tobias Peikert; Eunhee S Yi
Journal:  Int J Rheumatol       Date:  2012-05-27

8.  Cutoff Values of Serum IgG4 and Histopathological IgG4+ Plasma Cells for Diagnosis of Patients with IgG4-Related Disease.

Authors:  Yasufumi Masaki; Nozomu Kurose; Motohisa Yamamoto; Hiroki Takahashi; Takako Saeki; Atsushi Azumi; Shinji Nakada; Shoko Matsui; Tomoki Origuchi; Susumu Nishiyama; Kazunori Yamada; Mitsuhiro Kawano; Akira Hirabayashi; Keita Fujikawa; Tomoko Sugiura; Masanobu Horikoshi; Naoto Umeda; Hiroshi Minato; Takuji Nakamura; Haruka Iwao; Akio Nakajima; Miyuki Miki; Tomoyuki Sakai; Toshioki Sawaki; Takafumi Kawanami; Yoshimasa Fujita; Masao Tanaka; Toshihiro Fukushima; Katumi Eguchi; Susumu Sugai; Hisanori Umehara
Journal:  Int J Rheumatol       Date:  2012-05-10

9.  Complement C4 inhibits systemic autoimmunity through a mechanism independent of complement receptors CR1 and CR2.

Authors:  Z Chen; S B Koralov; G Kelsoe
Journal:  J Exp Med       Date:  2000-11-06       Impact factor: 14.307

Review 10.  IgG4-related disease and its pathogenesis-cross-talk between innate and acquired immunity.

Authors:  Hisanori Umehara; Akio Nakajima; Takuji Nakamura; Takafumi Kawanami; Masao Tanaka; Lingli Dong; Mitsuhiro Kawano
Journal:  Int Immunol       Date:  2014-07-14       Impact factor: 4.823

View more
  1 in total

Review 1.  The Role of IgG4 in Autoimmunity and Rheumatic Diseases.

Authors:  Maria Maslinska; Joanna Dmowska-Chalaba; Michal Jakubaszek
Journal:  Front Immunol       Date:  2022-01-25       Impact factor: 7.561

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.